The transaction is expected to close before the end of the year. Boston Scientific Corp. expects to record a gain in excess of $500 million upon closing, and total after-tax proceeds are estimated at approximately $1.2 billion.
Under the agreement, Boston Scientific will provide transitional services and products to Stryker. During the transition, products will be sold to Stryker at a cost.
Read the release on Stryker’s acquisition.
Read more coverage on Stryker:
– Stryker Reports a 7% Net Sales Increase for 3Q 2010
– Stryker’s Oren Gelman Discusses Trends Toward Single-Radius Knee Implant Design
– Stryker Acquires Gaymar Industries for $150M
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
